March 7 (Bloomberg) -- Getinge AB plunged the most since trading began in 1993 after the maker of hospital equipment said first-quarter profit will drop on higher costs to improve quality after regulatory inspections last year.
Getinge tumbled 21 percent to close at 182.80 kronor at 5:30 p.m. in Stockholm in trading of 10.6 million shares, about 16 times the daily average from the past three months. The company has a market value of 43.6 billion kronor ($6.8 billion).
Pretax profit will be 160 million kronor in the first quarter, the Getinge, Sweden-based company said in a statement today. Analysts predicted 628.7 million kronor, the average of six estimates compiled by Bloomberg.
The announcement marks the third time in little more than a year that Getinge has disappointed investors with its forecast. Getinge said in February 2013 that it wouldn’t meet its margin target, and in October it slumped after saying third-quarter profit would be less than forecast.
“At a time when management needs to rebuild trust, analysts and investors are left dumbfounded by a further surprise negative announcement,” Scott Bardo, an analyst with Berenberg Bank, said in a note to investors today. “Investor communication remains poor and this must be addressed.”
Getinge said last year that the U.S. Food and Drug Administration inspected a number of factories for the Medical Systems unit, which makes products including surgical tables, surgical lamps and fully-equipped pre-manufactured operating rooms.
The company made “significant improvements to enhance the quality management systems” at its factories after the inspections, Getinge said in December.
Consultants hired as a result to improve quality controls will cost 125 million kronor a quarter beginning with the first three months of this year and continue for a period of six to seven quarters, Getinge said today.
The first quarter will also be weak due to a “lower level of invoicing” for its capital goods, which represent 50 percent of its sales, the company said. Also, the cardiovascular division had a production disruption due to a change in raw materials by a supplier which cost 60 million kronor.
To contact the reporter on this story: Allison Connolly in London at firstname.lastname@example.org
To contact the editors responsible for this story: Phil Serafino at email@example.com Kim McLaughlin